Zhifei Biological's influenza vaccine supplementary application accepted, planned to extend to children aged 6-35 months

Jiemian··CN·Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Chongqing Zhifei Biological Products announced that its wholly-owned subsidiary Anhui Zhifei Longcom Biopharmaceutical has had its self-developed split influenza virus vaccine supplementary application accepted by the National Medical Products Administration, planning to add children aged 6-35 months to the currently approved population of those aged 3 years and above. The vaccine was approved for market in September 2025. If the supplementary application is approved, it will form an influenza vaccine series covering all age groups together with the company's already marketed quadrivalent influenza vaccine and its adjuvanted influenza vaccine under development. The company cautioned that the supplementary application must go through technical review, clinical trial site inspections and other procedures, and that the review progress and outcome are uncertain, with no significant impact on near-term performance.

Impact on assets 1

Others▲ · 1 stocks
Chongqing Zhifei Bio Products
300122
▲ PositiveRegulationrelevance

NMPA accepted the supplementary application to extend its split influenza vaccine to children aged 6-35 months, potentially broadening the approved population.

Off-coverage companies 1

安徽智飞龙科马生物制药有限公司Private▲ Positive
Regulationrelevance

Its self-developed split influenza virus vaccine's supplementary application was accepted by the NMPA to add children aged 6-35 months.

© 2026 MarketIVNews